S&P 500 Gains and Losses Today: Medical Device Makers ResMed, Insulet Lead Index
Major U.S. equities indexes ticked higher ahead of a potentially consequential earnings report from semiconductor giant Nvidia (NVDA) as well as key inflation and economic data set for release later in the week.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
RMD ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your ResMed Inc. investment
NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
ResMed Shares Breathing Life into Big Money Portfolios
Leading respiratory care device maker ResMed Inc. (RMD) is a profit producing machine.
RMD ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ResMed Inc.
NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ATTENTION RMD SHAREHOLDERS: Investors who lost money on ResMed Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
RMD ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ResMed Inc.
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
ResMed Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - RMD
NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
An Investigation Has Commenced on Behalf of ResMed Inc. Shareholders. Contact Levi & Korsinsky to Discuss your RMD Losses
NEW YORK, NY / ACCESSWIRE / August 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities
ResMed Inc. RMD reported fourth-quarter 2024 revenue of $1.22 billion, up 9% year-over-year and up 10% on a constant currency basis, in line with the consensus of $1.22 billion.
ResMed's (RMD) Q4 Earnings Surpass Estimates, Margins Expand
ResMed (RMD) delivers solid performance across all regions and business segments in the fourth quarter of fiscal 2024.
